Roggwil, March 7, 2022 – After a successful test of the first delivered devices from a 2nd contract manufacturer, a framework agreement for the supply of 2,000 pieces of tinniwell was concluded. The framework contract has a term of 36 months and the first delivery of 500 pieces will begin in June 2022.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG


Ms. Anke Rauterkus (Chief Executive Officer)

Bahnhofplatz 5

9322 Egnach


Switzerland

T. +41 714500668


a.rauterkus@resaphene.ch